Chimeric antigen receptor therapy meets mRNA technology

Trends Biotechnol. 2023 Sep 21:S0167-7799(23)00239-1. doi: 10.1016/j.tibtech.2023.08.005. Online ahead of print.ABSTRACTGenetically engineered immune cells expressing chimeric antigen receptors (CARs) have emerged as a new game changer in cancer immunotherapy. The utility of CAR T cell therapy against hematological malignancies has been validated in clinical practice. Other CAR immune cells are currently under investigation to improve the potency of CAR therapy in solid tumors. As a new class of therapeutic modalities, mRNA-based therapeutics hold enormous potential beyond COVID-19 mRNA vaccines. Arming immune cells with mRNA-encoded CARs represents a new frontier in cancer and beyond, enabling in vivo generation of CAR cells without causing transgene integration. In this review, we summarize recent advances in mRNA-based CAR immunotherapies and highlight their opportunities and challenges for the development of a new generation of living drugs.PMID:37741706 | DOI:10.1016/j.tibtech.2023.08.005
Source: Trends in Biotechnology - Category: Biotechnology Authors: Source Type: research